source
- AstraZeneca halts Phase 3 lung cancer trial of bispecific antibody volrustomig after interim data miss survival goalAstraZeneca announced termination of the Phase 3 study of its experimental bispecific antibody volrustomig in non‑small cell lung cancer. An interim data review by trial monitors indicated the dru…
- AstraZeneca reports positive late-stage results for Tagrisso-Orpathys combo and Enhertu in lung cancerAstraZeneca said on Monday that two separate late-stage studies in lung cancer have produced positive outcomes. One study evaluated a combination of the tyrosine-kinase inhibitor Tagrisso with the…Endpoints · 3d agoPositive readoutPositive